🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today, we announced that we're building the largest foundation model that's ever been built in oncology, in collaboration with AstraZeneca and Pathos. This project is the culmination of years of work. A foundation model like this has the potential to unlock a myriad of

We're looking forward to seeing you at #AACR25 in our hometown of Chicago. Head to Booth #1236 to meet the Tempus team, experience live demos of our newest technologies and discover how we are leveraging AI to advance precision medicine. Find more information here:

We’re excited to share that 18 abstracts, including one oral presentation, have been accepted for presentation at #AACR25. Attend a presentation and meet with the Tempus team at Booth #1236 to learn more about our research, which highlights the transformative impact of AI on

Join us today at 10:00am CT in South Hall A, Theater B to hear from Ryan Fukushima, Jonathan Ozeran and Robert Shoemaker, Ph.D., about leveraging machine learning models to accelerate discovery and unlock greater potential from real-world datasets. #AACR25

We're excited to announce Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is our proprietary approach to novel target identification that integrates real-world patient data (#RWD) with human-derived biological models and CRISPR-screens, all

Thank you to everyone who attended and asked insightful questions during our Exhibitor Spotlight Theater earlier today at #AACR25. If you couldn't make it, stop by Booth #1236 to hear more from the Tempus team about our latest scientific and clinical research findings.

🔊 Jerod Parsons, Ph.D, presenting "Enhancing Clonal Hematopoiesis Variant Detection in Tumor-Normal Matched Sequencing: Using Machine Learning" at #AACR25. This study addresses the challenge of accurately identifying clonal hematopoiesis (CH) variants in tumor-normal matched

We’re excited to announce the publication of “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants

Joining for the first session of the day: the #AI powered journey from discovery to deployment. Marina Sirota from UCSF Bakar Computational Health Sciences Institute, Ziad Obermeyer from Berkeley Public Health, John Axerio-Cilies from Tempus, and CPH’s Dr. Adam Yala. #conference #AIforall

🔊 John Guittar, PhD, presenting 'A novel approach to define ctDNA molecular response to immunotherapy" at #AACR25. Stop by Booth #1236 to learn more.

We recently launched a pan-cancer laboratory developed test that uses a suite of algorithms that leverage RNA-seq data to predict a patient’s likelihood of having a positive IHC result for key biomarkers, including HER2 and TROP2. Learn more about the key benefits for life

#AACR25 has officially come to a close and we're reflecting on an incredible meeting full of innovation and impactful research. In just a few packed days, we gathered as a team to share our latest research findings, and introduced new AI-enabled solutions to the oncology

We are excited to share that we are now leveraging our TIME Trial Network to expand support in phase I clinical trials. Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly

We are excited to announce the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be

Get real-time answers and uncover patient insights with Tempus One, our generative AI assistant built for healthcare providers and researchers. Discover its latest capabilities and enhancements at #ASCO25, or learn more here: tempus.co/3Z7nS9h

Today, we shared our Q1 2025 results, highlights include: - Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 - Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both

This #NationalNursesWeek, we extend our heartfelt thanks to the dedicated and exceptional nurses—both on the Tempus team and at our partner institutions—who inspire and drive the work we do. At Tempus, our mission to bring the power of precision medicine to every patient is made

Our Chief Scientific Officer, Kate Sasser, PhD, spoke on a panel yesterday at #MIGlobal about the power of artificial intelligence to transform the future of health, drive research, and empower patients and caregivers with the knowledge, insights, and agency to live longer,

Analytical Validation of Next-Generation Sequencing–Based Comprehensive Liquid Biopsy Assay for Therapy Selection. From Association for Molecular Pathology member author Dr. Brett Mahon and colleagues from Tempus Full text: jmdjournal.org/article/S1525-…

Join us for an upcoming webinar, “The RNA advantage: A multimodal approach to accelerating oncology R&D” with Rafael Rosengarten, PhD, CEO & Co-founder of Genialis and Justin Guinney, PhD, SVP of Cancer Genomics, Tempus. This session will explore the applications of